Food and Drug
Administration
Risk Communication Advisory Committee
February 28 - 29, 2008
FDA
Topic I: Background on FDA Risk Communication, February 28, 2008
Overview of Risk Communication at FDA, Nancy M. Ostrove, Ph.D., Senior Advisor for Risk Communication, FDA (2008-4347s1-01(ppt) (pdf)
Legal Authorities and Protections Relevant to Risk Communication: Speech FDA regulates William A. McConagha, Assistant Commissioner for Accountability and Integrity, FDA (2008-4347s1-02) (ppt) (pdf)
Legal Authorities and Protections Relevant to Risk Communication: Speech FDA generates, William A. McConagha, Assistant Commissioner for Accountability and Integrity, FDA (2008-4347s1-03) (ppt) (pdf)
New in FDA Amendments Act, Jarilyn Dupont, Director of Regulatory Policy, Office of Policy, FDA (2008-4347s1-04) (ppt) (pdf)
FDA research: Clearance requirements and implications, Steven L. Bradbard, Ph.D., Team Leader for Consumer Studies, Center for Food Safety and Applied Nutrition, FDA (2008-4347s1-05) (ppt) (pdf)
Existing Risk Communications Programs – Overview, Panel, FDA (2008-4347s1-06) (ppt) (pdf)
Topic II: FDA Draft Press Release Template on Product Recalls, February 29, 2008
Communication about Product Recalls, CAPT David Elder, Director, Office of Enforcement, FDA Office of Regulatory Affairs (2008-4347s2-01) (ppt) (pdf)
Literature Review: What do we know about the public’s awareness, understanding, and
perceptions of recalls concerning FDA-regulated products?, Amy Lando, M.P.P. Consumer Science Specialist, Center for Food Safety and Applied Nutrition, FDA (2008-4347s2-02) (ppt) (pdf)
Comments from FDA Consultant: Michael Wogalter, Ph.D., Professor of Psychology, North Carolina State University (2008-4347s2-03) (ppt) (pdf)
Open Public Hearing (Updated 7/22/08)
AdvaMed: Statement to the FDA Risk Communication Advisory Committee (pdf)
Heart Rhythm Society: Statement to the Food and Drug Administration Risk Communication Advisory Committee (pdf)
Up
| AC Home Page